热门资讯> 正文
Ligand通过收购Xoma Royalty恢复对花旗的收购
2026-07-22 03:35
- XOMA Royalty Corporation Depositary Shs Repr 1/1000th 8.375% Cum Conv Perp Red Pfd Rg Shs Series B(XOMAO) 0
- 强生(JNJ) 0
- 罗氏(ADR)(RHHBY) 0
- Citi has resumed its coverage of Ligand Pharmaceuticals (LGND) with a buy rating saying that its acquisition of XOMA Royalty adds a significant number of late-stage assets as well as a steady royalty stream.
- The acquisition, with an equity value of $739M, closed earlier in July.
- The bank has a price target of $387 (~32% return based on July 20 close).
- Analyst Yigal Nochomovitz noted that Ligand could significantly benefit from a contingent value right related to Johnson & Johnson's (JNJ) Tremfya (guselkumab) once ongoing litigation is resolved.
- He added that Ligand will also gain from Xoma's key commercial drivers, Roche (RHHBY) unit Genentech's Vabysmo (faricimab), Day One Biopharmaceuticals' Ojemda (tovorafenib), and Zevra Therapeutics (ZVRA) Miplyffa (arimoclomol).
More on Ligand Pharmaceuticals
- Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator
- Ligand Pharmaceuticals: The Bull Case Is A Biotech ARM, The Bear Case Is Just Another Royalty Trust
- Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript
- Ligand Pharmaceuticals prices $625M convertible debt offering
- Ligand prices proposed $550M convertible senior notes offering
推荐文章
美股前瞻 | 比特币一度突破7.8万美元！加密货币概念股盘前齐升；存储需求强劲！美光CEO称“全力生产也跟不上需求”
银色债券2026今起认购！保底息率4.25厘，每手3年累计派息至少1,275港元
华盛早报 | 贝森特两日救市！美债回购规模或超40亿美元；Anthropic冲击史上最大IPO；恒指季检结果，中际旭创、长飞光纤财报今日公布
美股前瞻 | 史诗级“轧空”来袭！比特币升破7.2万美元；业绩股齐遇冷！沃尔玛盘前大跌逾6%，阿里、网易均跌近4%
一图看懂 | AI与云业务表现强劲！阿里Q1营收2690亿元，同比增9%略超预期；阿里云外部商业化收入加速增至45%
一图看懂 | 泡泡玛特上半年营收171亿、净利50亿均大逊预期！星星人IP逆势暴涨580%；王宁称计划半年内大额回购20-50亿
Moderna暴涨177%！mRNA癌症疫苗迎来“ChatGPT时刻”？16只港美标的谁会接过下一棒？
“影子股”已暴涨90%！如何在Anthropic史上最大IPO前抢跑入局？最全攻略来了
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
